Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Short-Term Debt issuancesShort-Term Debt repayments
Ratios

Myriad Genetics (MYGN) Short-Term Debt issuances (2018 - 2025)

Historic Short-Term Debt issuances for Myriad Genetics (MYGN) over the last 4 years, with Q1 2025 value amounting to $40.0 million.

  • Myriad Genetics' Short-Term Debt issuances fell 3333.33% to $40.0 million in Q1 2025 from the same period last year, while for Sep 2025 it was $60.0 million, marking a year-over-year decrease of 5714.29%. This contributed to the annual value of $120.0 million for FY2024, which is 5000.0% up from last year.
  • Latest data reveals that Myriad Genetics reported Short-Term Debt issuances of $40.0 million as of Q1 2025, which was down 3333.33% from $20.0 million recorded in Q4 2024.
  • Over the past 5 years, Myriad Genetics' Short-Term Debt issuances peaked at $60.0 million during Q1 2024, and registered a low of $20.0 million during Q2 2024.
  • Moreover, its 3-year median value for Short-Term Debt issuances was $40.0 million (2023), whereas its average is $34.3 million.
  • In the last 5 years, Myriad Genetics' Short-Term Debt issuances tumbled by 5000.0% in 2024 and then crashed by 3333.33% in 2025.
  • Over the past 3 years, Myriad Genetics' Short-Term Debt issuances (Quarter) stood at $40.0 million in 2023, then crashed by 50.0% to $20.0 million in 2024, then soared by 100.0% to $40.0 million in 2025.
  • Its last three reported values are $40.0 million in Q1 2025, $20.0 million for Q4 2024, and $20.0 million during Q3 2024.